|
| Thursday, December 24, 2020 |
|
|
AIM ImmunoTech Announces that the ME/CFS Clinical Trial of its Drug Ampligen is Open for Enrollment to COVID-19 'Long Haulers' |
AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 "Long Hauler" portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a solicitation of patient enrollment. Patients in the trial are treated with AIM's flagship pipeline drug Ampligen.
more info >> |
|
| Thursday, February 27, 2020 |
|
|
AIM ImmunoTech joins with ChinaGoAbroad for Ampligen China Entry against COVID-19 |
| AIM ImmunoTech (NYSE American: AIM, or the Company) today announced that the Company has joined with ChinaGoAbroad (CGA) to facilitate the entry of AIM's experimental drug Ampligen into the People's Republic of China (PRC) for use as a prophylactic/early-onset therapeutic against COVID-19, the new SARS-like coronavirus infection that has reached epidemic proportions. more info >> |
|
| Tuesday, February 18, 2020 |
|
|
AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic |
| AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided its stockholders with an update on its efforts to develop Ampligen as a protective therapeutic and a vaccine in the new coronavirus epidemic. more info >> |
|
| Tuesday, February 11, 2020 |
|
|
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus |
| AIM ImmunoTech Inc. (NYSE American:AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company's efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. more info >> |
|
|
|
